CFO at Ascentage Pharma (AAPG) receives 18,584 RSU award

Rhea-AI Filing Summary

Misra Veet reported acquisition or exercise transactions in this Form 4 filing.

Ascentage Pharma Group International reported a compensation-related equity grant to its Chief Financial Officer, Veet Misra. The filing shows an award of 18,584 restricted stock units (RSUs) on April 20, 2026.

Each RSU represents a contingent right to receive one Ordinary Share of the company upon vesting. According to the disclosure, these RSUs vest immediately and have no expiration date. Following this grant, the CFO directly holds 18,584 RSUs, reflecting a new equity-based incentive aligned with the company’s share performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Misra Veet

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted stock units	18,584	$0.00	--

Holdings After Transaction: Restricted stock units — 18,584 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 18,584 units Transaction price per RSU: $0.0000 RSUs held after grant: 18,584 units

3 metrics

RSUs granted 18,584 units Grant to Chief Financial Officer on April 20, 2026

Transaction price per RSU $0.0000 Recorded grant price for the restricted stock units

RSUs held after grant 18,584 units Total restricted stock units directly held following the award

Key Terms

Restricted stock units, contingent right, Ordinary Share

3 terms

Restricted stock units financial

"Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one Ordinary Share of the Issuer upon vesting"

Ordinary Share financial

"to receive one Ordinary Share of the Issuer upon vesting"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Misra Veet

(Last) (First) (Middle)

C/O ASCENTAGE PHARMA GROUP INC.

700 KING FARM BLVD., SUITE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock units	$0	04/20/2026		A	V	18,584		(1)	(1)	Restricted stock units	18,584	$0	18,584	D

Explanation of Responses:

1. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest immediately and have no expiration date.

Remarks:

This form is filed using a special power of attorney.

	Thomas J. Knapp	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ascentage Pharma (AAPG) disclose?

Ascentage Pharma disclosed an equity grant to its Chief Financial Officer. The filing reports an award of 18,584 restricted stock units (RSUs), which are compensation-related instruments that convert into Ordinary Shares, giving the executive additional equity exposure tied directly to the company’s share performance.

How many restricted stock units did the AAPG CFO receive?

The Chief Financial Officer received 18,584 restricted stock units. Each RSU represents a contingent right to receive one Ordinary Share of Ascentage Pharma upon vesting, providing the executive with a direct equity incentive linked to future company performance and share value.

Do the AAPG CFO’s new RSUs have an exercise price or cost?

The RSU grant was recorded at a transaction price per unit of $0.0000. RSUs typically do not require a cash exercise; instead, they convert into Ordinary Shares upon vesting, functioning as a form of share-based compensation rather than a traditional stock option.

When do the AAPG CFO’s restricted stock units vest?

According to the filing footnote, the restricted stock units vest immediately. That means the Chief Financial Officer’s 18,584 RSUs become eligible to convert into Ordinary Shares without a waiting period, subject to the standard terms and conditions of the company’s equity compensation arrangements.

What does one AAPG restricted stock unit represent?

Each restricted stock unit represents a contingent right to receive one Ordinary Share of Ascentage Pharma. Once vested, the RSUs can settle in shares, effectively increasing the recipient’s equity stake and linking a portion of their compensation to the company’s stock performance.